There has been some use of Tocilizumab in response to Grade 2 or higher CRS to block IL-6 in CD-19 CAR-T therapy and has shown efficacy in limiting duration of CRS in patients as well as used as prevention for CRS in liquid cancers [96,97]. Here, IL6 is linked to congenital rubella syndrome.